Hemispherx Biopharma announces quarterly loss per share $0.11

By Reuters
May 15 (Reuters) - Hemispherx Biopharma Inc
* Hemispherx Biopharma announces financial results for the three months ended March 31, 2017
* Quarterly loss per share $0.11
* Hemispherx Biopharma- Have begun to generate and can now reasonably project growing future revenues from newly manufactured lots of ampligen for 2017
* Hemispherx Biopharma - Bridge loan established on May 12 to assist in funding expenses of manufacturing Ampligen to generate revenues for 2017, 2018
* Hemispherx Biopharma Inc - Cash, cash equivalents and marketable securities were about $3.7 million at March 31, 2017 versus $5.9 million as of Dec 31, 2016 Source text for Eikon: Further company coverage:

Sign up here.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Purchase Licensing Rights

Read Next